Welcome to our dedicated page for Charles Riv Labs Intl SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Charles River Laboratories International, Inc. (NYSE: CRL) provides direct access to the company’s regulatory disclosures, along with AI-powered tools that help interpret complex documents. Charles River operates in research and development in biotechnology within the professional, scientific, and technical services sector, and its filings offer detailed insight into how it manages growth, risk, governance, and capital allocation.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand segment performance across Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. These reports typically discuss demand trends, restructuring initiatives, portfolio refinement, and the use of non-GAAP measures that exclude items such as acquisition-related amortization, restructuring costs, and certain legal expenses. AI summaries can highlight key sections, such as discussions of organic revenue, operating margins, and the rationale for using non-GAAP metrics.
Current reports on Form 8-K are especially important for tracking material events at Charles River. Recent 8-K filings have described planned acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS, updates on Discovery and Safety Assessment demand indicators, the outcome of an SEC Division of Enforcement investigation into non-human primate sourcing, strategic review outcomes, and leadership changes including CEO succession and executive compensation arrangements. AI analysis can surface these items, explain their context, and point to related risk factor or management discussion sections in periodic reports.
Users interested in governance and executive arrangements can examine 8-K and 8-K/A filings detailing appointments, resignations, and compensation terms for senior leaders, as well as board decisions on stock repurchase authorizations and change-in-control agreements. While insider trading activity is disclosed separately on Forms 3, 4, and 5, this page is designed to link related ownership and compensation information to the broader narrative in 10-Ks, 10-Qs, and 8-Ks.
All filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help readers quickly identify the main points of lengthy documents, such as how acquisitions like K.F. (Cambodia) Ltd. and PathoQuest SAS are expected to affect Discovery and Safety Assessment or Biologics Testing operations, or how restructuring and portfolio divestitures relate to the company’s focus on core scientific capabilities and long-term shareholder value.
Charles River Laboratories International outlined improving demand and strategic moves ahead of a major healthcare conference. The company reported that demand in its Discovery and Safety Assessment (DSA) segment strengthened through the second half of 2025, with a preliminary DSA net book-to-bill of approximately 1.1x in the fourth quarter, meaning new DSA bookings exceeded revenue.
For 2026, the company expects the top end of its organic revenue growth guidance ranges to be at least flat for both the consolidated business and the DSA segment, with a cautious expectation of returning to revenue growth in the second half of 2026. Foreign exchange is expected to add 100–150 basis points to reported revenue growth, and incremental cost savings of more than $100M in 2026 are intended to offset cost inflation and support non-GAAP operating margin.
The company also plans two acquisitions: the assets of K.F. (Cambodia) Ltd. for about $510M, expected to be accretive to non-GAAP EPS by about $0.25 in 2026 and $0.60 in 2027, and the remaining 79% of PathoQuest SAS for €51.6M (about $60M), which is expected to generate $15–$20M of 2026 revenue but not materially affect 2026–2027 financial results.
Charles River Laboratories International, Inc. announced a planned leadership transition. On May 5, 2026, Chief Operating Officer Birgit Girshick will become Chief Executive Officer, succeeding James C. Foster, who will step down as CEO and Chair and is expected to remain a non-executive director. Lead Independent Director Dr. Martin Mackay is expected to become Chair of the Board on the same date.
Ms. Girshick’s compensation will be adjusted for her new role, with base salary set at $1,200,000 effective February 1, 2026, a target annual cash incentive equal to 100% of base salary effective May 1, 2026, and an initial equity grant with a target fair market value of $9,000,000, mostly in performance share units. In connection with a potential change in control, she would be eligible for severance equal to three times salary plus target bonus, three years of benefits, and outplacement services if terminated under specified conditions.
The Board size will increase from 11 to 12 directors as of the transition date to add Ms. Girshick, with consent from Elliott-affiliated funds under an existing cooperation agreement. Mr. Foster will receive restricted stock units with an underlying fair market value of $3,000,000, expected to be granted on March 2, 2026, vesting after two years, and is expected to receive standard non-executive director compensation thereafter.
Charles River Laboratories International, Inc. reported that demand indicators in its Discovery and Safety Assessment (DSA) segment are improving. At an investor presentation at the Evercore 8th Annual Healthcare Conference, management stated that DSA net book-to-bill has improved each month since the beginning of the third fiscal quarter of 2025. The company also noted that typical holiday seasonality in the fourth quarter and early January could affect near-term proposal and booking activity, but emphasized its encouragement with the positive momentum and upward trends observed since the middle of fiscal 2025.
Charles River Laboratories International, Inc. (CRL) announced the conclusion of an SEC investigation without an enforcement recommendation. The SEC’s Division of Enforcement informed the company that, based on the information available to it, it does not intend to recommend an enforcement action related to the company’s sourcing of non-human primates and related disclosures. The company’s Audit Committee also completed its own independent investigation into the same matters, reporting no material findings. This removes a regulatory overhang that had been disclosed since May 2023.
Charles River Laboratories (CRL): Schedule 13G/A reports that Nomura Holdings, Inc. beneficially owns 807,923 shares of CRL common stock, equal to 1.6% of the class. The ownership is held with sole voting and dispositive power and is attributed to Nomura subsidiaries Nomura Global Financial Products, Inc., Nomura Securities International, Inc., and Nomura International PLC.
The percentage is based on 49,215,000 shares outstanding as of September 27, 2025. Nomura certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Charles River Laboratories (CRL): Schedule 13G/A ownership update. Wellington Management Group LLP and affiliated entities filed Amendment No. 2 reporting beneficial ownership of 3,190,467 shares of CRL common stock, representing 6.48% of the class as of the event date 09/30/2025. The filing indicates shared voting and shared dispositive power across Wellington entities, with no sole voting or dispositive power reported.
The certification states the shares were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. The securities are held of record by clients of Wellington’s advisory affiliates, and no such client is known to hold more than five percent of the class.
Charles River Laboratories (CRL) insider update: Interim CFO Michael G. Knell reported an acquisition of 2,926 shares of common stock at $170.88 on 11/06/2025 (transaction code A), increasing his beneficial ownership to 13,460 shares, held directly.
The filing notes these are restricted stock units with a two-step vesting schedule: 50% vest on November 6, 2026 and the remaining 50% on November 6, 2027.
Charles River Laboratories (CRL) reported Q3 2025 results. Total revenue was $1,004,852,000, slightly below last year’s $1,009,763,000. Service revenue decreased to $808,042,000, while product revenue rose to $196,810,000. Operating income increased to $133,799,000, but higher tax expense and unfavorable other income led to net income attributable to CRL of $54,422,000 versus $69,657,000 a year ago. Diluted EPS was $1.10 compared with $1.33.
By segment, Q3 revenue was: DSA $600,685,000; RMS $213,474,000; and Manufacturing $190,693,000. Operating income improved in RMS and was roughly flat in Manufacturing, while DSA softened slightly. The company changed useful lives for certain assets, reducing depreciation and increasing EPS by about $0.07 in the quarter and $0.21 year‑to‑date.
Year to date, revenue was $3,021,155,000 with diluted EPS of $2.65. Operating cash flow reached $590,126,000, funding $130,202,000 of capex and $360,577,000 of share repurchases. CRL repurchased 2.1 million shares for $350,000,000 and approved a new $1.0 billion authorization on October 29, 2025.
Charles River Laboratories International, Inc. furnished an update on its business by issuing a press release with financial results for the third quarter ended September 27, 2025. The press release was provided as Exhibit 99.1 and contains forward‑looking statements under the Private Securities Litigation Reform Act of 1995.
The information under Item 2.02 is being furnished and is not deemed filed under the Exchange Act, except as expressly incorporated by reference in future filings.
Charles River Laboratories International, Inc. filed an amendment to a prior report about its leadership change to add details on interim Chief Financial Officer Michael G. Knell’s compensation. Effective September 28, 2025, his annual base salary will be increased to $500,000. Starting October 1, 2025, he will also receive a $10,000 monthly cash payment during his term as interim Chief Financial Officer.
In addition, the Compensation Committee approved a one-time grant of restricted stock units with a grant value of $500,000 in the company’s common stock, to be granted on November 6, 2025. Half of these units will vest on the first anniversary of the grant date and the remaining half on the second anniversary, aligning part of his compensation with the company’s long‑term performance.